By VETTAPHARMA reporter: GRAIL, Inc. announced results from the NHS-Galleri trial, a major study evaluating annual multi-cancer screening with the Galleri® blood test in England’s National Health Service among approximately 142,000 adults aged 50–77. While the trial did not meet the combined primary endpoint of reducing all Stage III and IV cancers, it showed significant improvements in cancer detection patterns that could influence future screening strategies and clinical decision-making.
In comparison with standard NHS screening alone, the addition of the Galleri test led to a substantial reduction in Stage IV cancer diagnoses and a notable increase in early-stage (Stage I and II) detection for a prespecified set of hard-to-detect cancers. Early detection is widely associated with better treatment outcomes and survival, pointing to potential clinical benefits for patients undergoing regular screening.
Overall cancer detection rates were four times higher with the combined Galleri and standard screening approach versus standard care alone, including for cancers such as breast, colorectal, cervical, and high-risk lung cancers, which can be challenging to diagnose early through conventional methods. There was also a marked reduction in cancers identified through emergency presentation, a setting typically linked with worse prognoses.
GRAIL leadership emphasized that these findings support the potential value of multi-cancer early detection (MCED) testing in population health strategies and may inform ongoing policy discussions about broader screening adoption. The trial data will contribute to regulatory filings, including a pending PMAsubmission with the U.S. Food and Drug Administration, and will be presented in detail at major scientific conferences such as ASCO 2026.
Source credit:
- GRAIL, Inc. (2026, February 19). Landmark NHS-Galleri trial demonstrates a substantial reduction in Stage IV cancer diagnoses, increased Stage I and II detection of deadly cancers, and four-fold higher cancer detection rate. Click here
